Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting
暂无分享,去创建一个
Jennifer L Hunt | D. Bigner | J. Grandis | F. Furnari | J. Hunt | S. Xi | M. Lango | M. Graner | S. Thomas | J. Sok | W. Gooding | Darell D Bigner | William E Gooding | Frank B Furnari | Sichuan Xi | Jennifer R Grandis | Michael W Graner | C. Wikstrand | Francesca M. Coppelli | Sufi M Thomas | Carol J Wikstrand | John C Sok | Francesca M Coppelli | Miriam N Lango | Maria L Freilino | M. Freilino | S. Thomas
[1] A Guha,et al. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. , 1999, Neurosurgery.
[2] D. Bigner,et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. , 1993, Cancer research.
[3] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[4] J. Grandis,et al. Retinoic acid normalizes the increased gene transcription rate of TGF–α and EGFR in head and neck cancer cell lines , 1996, Nature Medicine.
[5] J. Grandis,et al. Targeting epidermal growth factor receptor in head and neck cancer , 2003 .
[6] C. A. Thomas,et al. Molecular cloning. , 1977, Advances in pathobiology.
[7] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[8] R. Day,et al. Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival , 1998 .
[9] C. James,et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.
[10] Ruth Katz,et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.
[11] W. Cavenee,et al. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[12] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[13] H. Zwierzina,et al. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. , 2006, European journal of cancer.
[14] R. Todd,et al. Intragenic mutation analysis of the human epidermal growth factor receptor (EGFR) gene in malignant human oral keratinocytes. , 1999, Cancer research.
[15] P. Humphrey,et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[16] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[17] A. Scott,et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. , 2001, Cancer research.
[18] K. Ichimura,et al. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas , 2005, Journal of Molecular Medicine.
[19] K Kian Ang,et al. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. , 2004, International journal of radiation oncology, biology, physics.
[20] Alicia Samuels,et al. Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.
[21] M. Hidalgo,et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] Suk Woo Nam,et al. Somatic Mutations of EGFR Gene in Squamous Cell Carcinoma of the Head and Neck , 2005, Clinical Cancer Research.
[23] J. Contessa,et al. Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells , 2002, Oncogene.
[24] G. Tortora,et al. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. , 2003, European journal of cancer.
[25] J. Welsh,et al. Ligand-induced transformation by a noninternalizing epidermal growth factor receptor. , 1990, Science.
[26] H. Wiley,et al. The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.
[27] J. Biegel,et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. , 1995, Cancer research.
[28] J. Grandis,et al. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl‐2 expression and increased susceptibility to cisplatin‐induced apoptosis , 2004, Head & neck.
[29] A. Friedman,et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] J. Grandis,et al. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. , 1993, Cancer research.
[31] O. Bogler,et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.
[32] D. O’Rourke,et al. Expression of Oncogenic Epidermal Growth Factor Receptor Family Kinases Induces Paclitaxel Resistance and Alters β-Tubulin Isotype Expression* , 2000, The Journal of Biological Chemistry.
[33] R. B. Montgomery,et al. Constitutive Activation of Phosphatidylinositol 3-Kinase by a Naturally Occurring Mutant Epidermal Growth Factor Receptor* , 1998, The Journal of Biological Chemistry.
[34] A. Schueler,et al. Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and neck (SCCHN) refractory to first-line platinum-based therapies , 2005 .
[35] D. Bigner,et al. EGF mutant receptor vIII as a molecular target in cancer therapy. , 2001, Endocrine-related cancer.
[36] A. Godwin,et al. Expression of constitutively activated EGFRvlll in non‐small cell lung cancer , 2003, Cancer science.
[37] Kenji Tada,et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.
[38] S. Taylor. Head and neck cancer. , 1991, Cancer chemotherapy and biological response modifiers.
[39] C. James,et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[40] R. Todd,et al. Expression of a truncated epidermal growth factor receptor in oral squamous cell carcinomas. , 2000, Cancer letters.
[41] R. McLendon,et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. , 1995, Cancer research.
[42] J. Wilson,et al. Cisplatinum and Bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial , 2004, Cancer Chemotherapy and Pharmacology.
[43] Careen K. Tang,et al. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis , 2002, International journal of cancer.
[44] A. Scott,et al. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. , 2001, Cancer research.
[45] Udo Greiser,et al. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. , 2003, Cancer research.
[46] R. McLendon,et al. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. , 1997, Cancer research.
[47] B. Zoll,et al. Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis , 1995, Journal of Neurology.
[48] W. Cavenee,et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[49] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[50] E. Bernhard,et al. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin , 2004, Oncogene.
[51] E. Vokes,et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] J. Mendelsohn,et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. , 1983, Molecular biology & medicine.
[53] J. Grandis,et al. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. , 2004, Cancer treatment reviews.
[54] C. Mamot,et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. , 2005, Cancer research.
[55] G. Riggins,et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. , 2002, Cancer research.
[56] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[57] H. Varmus,et al. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. , 1998, Genes & development.
[58] Vivian Wai Yan Lui,et al. EGFR-mediated cell cycle regulation. , 2002, Anticancer research.
[59] P. Humphrey,et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[60] M. Meyerson,et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[61] Allan H Friedman,et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.